nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—pancreatic cancer—germ cell cancer	0.575	1	CtDrD
Erlotinib—UGT1A1—Etoposide—germ cell cancer	0.0299	0.132	CbGbCtD
Erlotinib—ABCG2—Dactinomycin—germ cell cancer	0.0291	0.129	CbGbCtD
Erlotinib—CYP3A5—Ifosfamide—germ cell cancer	0.0191	0.0841	CbGbCtD
Erlotinib—CYP2C8—Ifosfamide—germ cell cancer	0.0183	0.0808	CbGbCtD
Erlotinib—ABCG2—Cisplatin—germ cell cancer	0.0167	0.0738	CbGbCtD
Erlotinib—ABCG2—Etoposide—germ cell cancer	0.0164	0.0725	CbGbCtD
Erlotinib—ABCG2—Methotrexate—germ cell cancer	0.0109	0.0479	CbGbCtD
Erlotinib—ABCB1—Dactinomycin—germ cell cancer	0.0105	0.0463	CbGbCtD
Erlotinib—CYP3A5—Etoposide—germ cell cancer	0.00911	0.0402	CbGbCtD
Erlotinib—CYP2C8—Etoposide—germ cell cancer	0.00876	0.0386	CbGbCtD
Erlotinib—ALB—Methotrexate—germ cell cancer	0.00749	0.033	CbGbCtD
Erlotinib—CYP3A4—Ifosfamide—germ cell cancer	0.00743	0.0328	CbGbCtD
Erlotinib—CYP1A2—Etoposide—germ cell cancer	0.00678	0.0299	CbGbCtD
Erlotinib—ABCB1—Vinblastine—germ cell cancer	0.00658	0.029	CbGbCtD
Erlotinib—CYP2D6—Vinblastine—germ cell cancer	0.0062	0.0274	CbGbCtD
Erlotinib—ABCB1—Cisplatin—germ cell cancer	0.00603	0.0266	CbGbCtD
Erlotinib—ABCB1—Etoposide—germ cell cancer	0.00593	0.0262	CbGbCtD
Erlotinib—CYP3A4—Vinblastine—germ cell cancer	0.00394	0.0174	CbGbCtD
Erlotinib—ABCB1—Methotrexate—germ cell cancer	0.00392	0.0173	CbGbCtD
Erlotinib—CYP3A4—Etoposide—germ cell cancer	0.00355	0.0157	CbGbCtD
Erlotinib—EPHA6—head—germ cell cancer	0.000357	0.00531	CbGeAlD
Erlotinib—JAK3—head—germ cell cancer	0.000357	0.00531	CbGeAlD
Erlotinib—TNK1—female gonad—germ cell cancer	0.000356	0.00531	CbGeAlD
Erlotinib—ABL2—pituitary gland—germ cell cancer	0.000351	0.00523	CbGeAlD
Erlotinib—EGFR—uterus—germ cell cancer	0.000349	0.00519	CbGeAlD
Erlotinib—CYP3A4—urine—germ cell cancer	0.000348	0.00517	CbGeAlD
Erlotinib—MKNK1—decidua—germ cell cancer	0.000347	0.00517	CbGeAlD
Erlotinib—SLK—telencephalon—germ cell cancer	0.000347	0.00517	CbGeAlD
Erlotinib—JAK3—testis—germ cell cancer	0.000344	0.00513	CbGeAlD
Erlotinib—EPHA6—testis—germ cell cancer	0.000344	0.00513	CbGeAlD
Erlotinib—MAP2K5—trigeminal ganglion—germ cell cancer	0.000343	0.00511	CbGeAlD
Erlotinib—CYP2D6—urine—germ cell cancer	0.000342	0.00509	CbGeAlD
Erlotinib—PIP4K2C—gonad—germ cell cancer	0.00034	0.00507	CbGeAlD
Erlotinib—PIP4K2C—pituitary gland—germ cell cancer	0.000332	0.00495	CbGeAlD
Erlotinib—TNK1—endocrine gland—germ cell cancer	0.000332	0.00494	CbGeAlD
Erlotinib—SLK—decidua—germ cell cancer	0.000329	0.0049	CbGeAlD
Erlotinib—FLT3—adrenal gland—germ cell cancer	0.000328	0.00489	CbGeAlD
Erlotinib—HIPK4—brain—germ cell cancer	0.000327	0.00487	CbGeAlD
Erlotinib—ULK3—gonad—germ cell cancer	0.000325	0.00484	CbGeAlD
Erlotinib—MAP3K19—head—germ cell cancer	0.000324	0.00482	CbGeAlD
Erlotinib—LTK—brain—germ cell cancer	0.000323	0.00481	CbGeAlD
Erlotinib—ULK3—uterus—germ cell cancer	0.000323	0.00481	CbGeAlD
Erlotinib—PIP4K2C—medulla oblongata—germ cell cancer	0.000321	0.00477	CbGeAlD
Erlotinib—JAK3—cerebellum—germ cell cancer	0.000318	0.00474	CbGeAlD
Erlotinib—FLT3—bone marrow—germ cell cancer	0.000318	0.00473	CbGeAlD
Erlotinib—ULK3—pituitary gland—germ cell cancer	0.000317	0.00472	CbGeAlD
Erlotinib—TNK1—testis—germ cell cancer	0.000316	0.00471	CbGeAlD
Erlotinib—ABL2—adrenal gland—germ cell cancer	0.000314	0.00467	CbGeAlD
Erlotinib—MAP3K19—testis—germ cell cancer	0.000313	0.00466	CbGeAlD
Erlotinib—LTK—lymph node—germ cell cancer	0.000312	0.00465	CbGeAlD
Erlotinib—FLT3—female gonad—germ cell cancer	0.000306	0.00456	CbGeAlD
Erlotinib—EGFR—adrenal gland—germ cell cancer	0.000306	0.00456	CbGeAlD
Erlotinib—ULK3—medulla oblongata—germ cell cancer	0.000306	0.00456	CbGeAlD
Erlotinib—MKNK1—gonad—germ cell cancer	0.000306	0.00456	CbGeAlD
Erlotinib—MAP2K5—brainstem—germ cell cancer	0.000304	0.00452	CbGeAlD
Erlotinib—MKNK1—pituitary gland—germ cell cancer	0.000298	0.00444	CbGeAlD
Erlotinib—PIP4K2C—adrenal gland—germ cell cancer	0.000297	0.00442	CbGeAlD
Erlotinib—PIP4K2C—midbrain—germ cell cancer	0.000293	0.00436	CbGeAlD
Erlotinib—ABL2—female gonad—germ cell cancer	0.000292	0.00435	CbGeAlD
Erlotinib—TNK1—cerebellum—germ cell cancer	0.000292	0.00435	CbGeAlD
Erlotinib—MKNK1—medulla oblongata—germ cell cancer	0.000288	0.00429	CbGeAlD
Erlotinib—SLK—uterus—germ cell cancer	0.000288	0.00429	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—germ cell cancer	0.000287	0.00427	CbGeAlD
Erlotinib—STK10—decidua—germ cell cancer	0.000286	0.00426	CbGeAlD
Erlotinib—PIP4K2C—spinal cord—germ cell cancer	0.000286	0.00426	CbGeAlD
Erlotinib—EGFR—female gonad—germ cell cancer	0.000285	0.00425	CbGeAlD
Erlotinib—FLT3—endocrine gland—germ cell cancer	0.000285	0.00424	CbGeAlD
Erlotinib—ULK3—adrenal gland—germ cell cancer	0.000283	0.00422	CbGeAlD
Erlotinib—SLK—pituitary gland—germ cell cancer	0.000283	0.00421	CbGeAlD
Erlotinib—ULK3—midbrain—germ cell cancer	0.00028	0.00416	CbGeAlD
Erlotinib—AURKC—brain—germ cell cancer	0.000279	0.00415	CbGeAlD
Erlotinib—PIP4K2C—female gonad—germ cell cancer	0.000277	0.00412	CbGeAlD
Erlotinib—ULK3—bone marrow—germ cell cancer	0.000274	0.00408	CbGeAlD
Erlotinib—ULK3—spinal cord—germ cell cancer	0.000273	0.00406	CbGeAlD
Erlotinib—SLK—medulla oblongata—germ cell cancer	0.000273	0.00406	CbGeAlD
Erlotinib—FLT3—testis—germ cell cancer	0.000272	0.00404	CbGeAlD
Erlotinib—MAP2K5—telencephalon—germ cell cancer	0.00027	0.00401	CbGeAlD
Erlotinib—AURKC—lymph node—germ cell cancer	0.00027	0.00401	CbGeAlD
Erlotinib—MKNK1—adrenal gland—germ cell cancer	0.000267	0.00397	CbGeAlD
Erlotinib—ABL1—trigeminal ganglion—germ cell cancer	0.000265	0.00394	CbGeAlD
Erlotinib—ULK3—female gonad—germ cell cancer	0.000264	0.00393	CbGeAlD
Erlotinib—MKNK1—midbrain—germ cell cancer	0.000263	0.00392	CbGeAlD
Erlotinib—ABL2—testis—germ cell cancer	0.000259	0.00386	CbGeAlD
Erlotinib—EPHA6—brain—germ cell cancer	0.000258	0.00385	CbGeAlD
Erlotinib—JAK3—brain—germ cell cancer	0.000258	0.00385	CbGeAlD
Erlotinib—MKNK1—bone marrow—germ cell cancer	0.000258	0.00384	CbGeAlD
Erlotinib—PIP4K2C—endocrine gland—germ cell cancer	0.000257	0.00383	CbGeAlD
Erlotinib—MKNK1—spinal cord—germ cell cancer	0.000257	0.00382	CbGeAlD
Erlotinib—ABL1—embryo—germ cell cancer	0.000256	0.00381	CbGeAlD
Erlotinib—MAP2K5—decidua—germ cell cancer	0.000256	0.0038	CbGeAlD
Erlotinib—PIP4K2C—head—germ cell cancer	0.000254	0.00378	CbGeAlD
Erlotinib—EGFR—testis—germ cell cancer	0.000253	0.00377	CbGeAlD
Erlotinib—SLK—adrenal gland—germ cell cancer	0.000253	0.00376	CbGeAlD
Erlotinib—STK10—gonad—germ cell cancer	0.000252	0.00375	CbGeAlD
Erlotinib—FLT3—cerebellum—germ cell cancer	0.000251	0.00374	CbGeAlD
Erlotinib—STK10—uterus—germ cell cancer	0.00025	0.00373	CbGeAlD
Erlotinib—JAK3—lymph node—germ cell cancer	0.00025	0.00372	CbGeAlD
Erlotinib—SLK—midbrain—germ cell cancer	0.000249	0.00371	CbGeAlD
Erlotinib—MKNK1—female gonad—germ cell cancer	0.000249	0.0037	CbGeAlD
Erlotinib—ULK3—endocrine gland—germ cell cancer	0.000246	0.00366	CbGeAlD
Erlotinib—PIP4K2C—testis—germ cell cancer	0.000245	0.00365	CbGeAlD
Erlotinib—SLK—bone marrow—germ cell cancer	0.000244	0.00364	CbGeAlD
Erlotinib—SLK—spinal cord—germ cell cancer	0.000243	0.00362	CbGeAlD
Erlotinib—ULK3—head—germ cell cancer	0.000243	0.00361	CbGeAlD
Erlotinib—ABL2—cerebellum—germ cell cancer	0.00024	0.00357	CbGeAlD
Erlotinib—TNK1—brain—germ cell cancer	0.000237	0.00353	CbGeAlD
Erlotinib—SLK—female gonad—germ cell cancer	0.000235	0.00351	CbGeAlD
Erlotinib—MAP3K19—brain—germ cell cancer	0.000235	0.0035	CbGeAlD
Erlotinib—ABL1—brainstem—germ cell cancer	0.000234	0.00349	CbGeAlD
Erlotinib—ULK3—testis—germ cell cancer	0.000234	0.00349	CbGeAlD
Erlotinib—EGFR—cerebellum—germ cell cancer	0.000234	0.00348	CbGeAlD
Erlotinib—MKNK1—endocrine gland—germ cell cancer	0.000231	0.00344	CbGeAlD
Erlotinib—TNK1—lymph node—germ cell cancer	0.000229	0.00341	CbGeAlD
Erlotinib—MKNK1—head—germ cell cancer	0.000228	0.0034	CbGeAlD
Erlotinib—ABL1—eye—germ cell cancer	0.000228	0.0034	CbGeAlD
Erlotinib—PIP4K2C—cerebellum—germ cell cancer	0.000227	0.00337	CbGeAlD
Erlotinib—ABL1—retina—germ cell cancer	0.000226	0.00337	CbGeAlD
Erlotinib—MKNK1—testis—germ cell cancer	0.000221	0.00328	CbGeAlD
Erlotinib—STK10—adrenal gland—germ cell cancer	0.00022	0.00327	CbGeAlD
Erlotinib—MAP2K5—pituitary gland—germ cell cancer	0.00022	0.00327	CbGeAlD
Erlotinib—ULK3—cerebellum—germ cell cancer	0.000216	0.00322	CbGeAlD
Erlotinib—Hepatobiliary disease—Ifosfamide—germ cell cancer	0.000213	0.00225	CcSEcCtD
Erlotinib—STK10—bone marrow—germ cell cancer	0.000212	0.00316	CbGeAlD
Erlotinib—Chills—Bleomycin—germ cell cancer	0.000212	0.00224	CcSEcCtD
Erlotinib—MAP2K5—medulla oblongata—germ cell cancer	0.000212	0.00315	CbGeAlD
Erlotinib—SLCO2B1—telencephalon—germ cell cancer	0.00021	0.00312	CbGeAlD
Erlotinib—SLK—testis—germ cell cancer	0.000209	0.00311	CbGeAlD
Erlotinib—Alopecia—Bleomycin—germ cell cancer	0.000209	0.0022	CcSEcCtD
Erlotinib—Erythema multiforme—Dactinomycin—germ cell cancer	0.000208	0.0022	CcSEcCtD
Erlotinib—ABL1—telencephalon—germ cell cancer	0.000208	0.0031	CbGeAlD
Erlotinib—Toxic epidermal necrolysis—Etoposide—germ cell cancer	0.000207	0.00219	CcSEcCtD
Erlotinib—Erythema—Bleomycin—germ cell cancer	0.000206	0.00217	CcSEcCtD
Erlotinib—STK10—female gonad—germ cell cancer	0.000205	0.00305	CbGeAlD
Erlotinib—MKNK1—cerebellum—germ cell cancer	0.000204	0.00303	CbGeAlD
Erlotinib—Alanine aminotransferase increased—Etoposide—germ cell cancer	0.000203	0.00215	CcSEcCtD
Erlotinib—Haemoglobin—Ifosfamide—germ cell cancer	0.000203	0.00214	CcSEcCtD
Erlotinib—Haemorrhage—Ifosfamide—germ cell cancer	0.000202	0.00213	CcSEcCtD
Erlotinib—Hepatitis—Ifosfamide—germ cell cancer	0.000202	0.00213	CcSEcCtD
Erlotinib—Urinary tract disorder—Ifosfamide—germ cell cancer	0.000199	0.0021	CcSEcCtD
Erlotinib—Dysphagia—Etoposide—germ cell cancer	0.000199	0.0021	CcSEcCtD
Erlotinib—SLCO2B1—decidua—germ cell cancer	0.000199	0.00296	CbGeAlD
Erlotinib—ABL1—skin of body—germ cell cancer	0.000198	0.00296	CbGeAlD
Erlotinib—Connective tissue disorder—Ifosfamide—germ cell cancer	0.000198	0.00209	CcSEcCtD
Erlotinib—Urethral disorder—Ifosfamide—germ cell cancer	0.000198	0.00209	CcSEcCtD
Erlotinib—Chills—Dactinomycin—germ cell cancer	0.000198	0.00209	CcSEcCtD
Erlotinib—ABL1—decidua—germ cell cancer	0.000197	0.00293	CbGeAlD
Erlotinib—FLT3—lymph node—germ cell cancer	0.000197	0.00293	CbGeAlD
Erlotinib—MAP2K5—adrenal gland—germ cell cancer	0.000196	0.00292	CbGeAlD
Erlotinib—Inflammation—Methotrexate—germ cell cancer	0.000196	0.00207	CcSEcCtD
Erlotinib—Alopecia—Dactinomycin—germ cell cancer	0.000195	0.00205	CcSEcCtD
Erlotinib—ABL2—brain—germ cell cancer	0.000195	0.0029	CbGeAlD
Erlotinib—Thrombocytopenia—Vinblastine—germ cell cancer	0.000194	0.00205	CcSEcCtD
Erlotinib—MAP2K5—midbrain—germ cell cancer	0.000194	0.00288	CbGeAlD
Erlotinib—CYP1B1—eye—germ cell cancer	0.000193	0.00288	CbGeAlD
Erlotinib—SLK—cerebellum—germ cell cancer	0.000193	0.00287	CbGeAlD
Erlotinib—Erythema—Dactinomycin—germ cell cancer	0.000192	0.00202	CcSEcCtD
Erlotinib—Acute coronary syndrome—Cisplatin—germ cell cancer	0.000191	0.00202	CcSEcCtD
Erlotinib—Erythema multiforme—Ifosfamide—germ cell cancer	0.000191	0.00201	CcSEcCtD
Erlotinib—Renal failure—Cisplatin—germ cell cancer	0.000191	0.00201	CcSEcCtD
Erlotinib—STK10—endocrine gland—germ cell cancer	0.00019	0.00284	CbGeAlD
Erlotinib—Neuropathy peripheral—Cisplatin—germ cell cancer	0.00019	0.00201	CcSEcCtD
Erlotinib—Myocardial infarction—Cisplatin—germ cell cancer	0.00019	0.00201	CcSEcCtD
Erlotinib—EGFR—brain—germ cell cancer	0.00019	0.00283	CbGeAlD
Erlotinib—Anorexia—Vinblastine—germ cell cancer	0.000189	0.002	CcSEcCtD
Erlotinib—Stomatitis—Cisplatin—germ cell cancer	0.000189	0.00199	CcSEcCtD
Erlotinib—MAP2K5—spinal cord—germ cell cancer	0.000189	0.00281	CbGeAlD
Erlotinib—Eye disorder—Ifosfamide—germ cell cancer	0.000189	0.00199	CcSEcCtD
Erlotinib—Conjunctivitis—Cisplatin—germ cell cancer	0.000188	0.00199	CcSEcCtD
Erlotinib—ABL2—lymph node—germ cell cancer	0.000188	0.0028	CbGeAlD
Erlotinib—STK10—head—germ cell cancer	0.000188	0.0028	CbGeAlD
Erlotinib—Neutropenia—Etoposide—germ cell cancer	0.000186	0.00197	CcSEcCtD
Erlotinib—Melaena—Methotrexate—germ cell cancer	0.000186	0.00196	CcSEcCtD
Erlotinib—PIP4K2C—brain—germ cell cancer	0.000184	0.00274	CbGeAlD
Erlotinib—EGFR—lymph node—germ cell cancer	0.000183	0.00273	CbGeAlD
Erlotinib—Hepatobiliary disease—Cisplatin—germ cell cancer	0.000183	0.00194	CcSEcCtD
Erlotinib—MAP2K5—female gonad—germ cell cancer	0.000183	0.00272	CbGeAlD
Erlotinib—Mediastinal disorder—Ifosfamide—germ cell cancer	0.000182	0.00192	CcSEcCtD
Erlotinib—STK10—testis—germ cell cancer	0.000182	0.0027	CbGeAlD
Erlotinib—Skin exfoliation—Methotrexate—germ cell cancer	0.000182	0.00192	CcSEcCtD
Erlotinib—Chills—Ifosfamide—germ cell cancer	0.000181	0.00191	CcSEcCtD
Erlotinib—Arrhythmia—Ifosfamide—germ cell cancer	0.00018	0.0019	CcSEcCtD
Erlotinib—UGT1A1—endocrine gland—germ cell cancer	0.00018	0.00268	CbGeAlD
Erlotinib—Cough—Bleomycin—germ cell cancer	0.000179	0.00189	CcSEcCtD
Erlotinib—Pneumonia—Etoposide—germ cell cancer	0.000179	0.00189	CcSEcCtD
Erlotinib—Alopecia—Ifosfamide—germ cell cancer	0.000178	0.00188	CcSEcCtD
Erlotinib—PIP4K2C—lymph node—germ cell cancer	0.000178	0.00265	CbGeAlD
Erlotinib—Infestation—Etoposide—germ cell cancer	0.000178	0.00187	CcSEcCtD
Erlotinib—Infestation NOS—Etoposide—germ cell cancer	0.000178	0.00187	CcSEcCtD
Erlotinib—Mental disorder—Ifosfamide—germ cell cancer	0.000177	0.00187	CcSEcCtD
Erlotinib—CYP1B1—telencephalon—germ cell cancer	0.000176	0.00262	CbGeAlD
Erlotinib—Stevens-Johnson syndrome—Etoposide—germ cell cancer	0.000176	0.00186	CcSEcCtD
Erlotinib—ULK3—brain—germ cell cancer	0.000176	0.00262	CbGeAlD
Erlotinib—Erythema—Ifosfamide—germ cell cancer	0.000176	0.00186	CcSEcCtD
Erlotinib—Malnutrition—Ifosfamide—germ cell cancer	0.000176	0.00186	CcSEcCtD
Erlotinib—Acute coronary syndrome—Etoposide—germ cell cancer	0.000175	0.00185	CcSEcCtD
Erlotinib—Chest pain—Bleomycin—germ cell cancer	0.000175	0.00185	CcSEcCtD
Erlotinib—Myalgia—Bleomycin—germ cell cancer	0.000175	0.00185	CcSEcCtD
Erlotinib—Renal failure—Etoposide—germ cell cancer	0.000175	0.00184	CcSEcCtD
Erlotinib—Neuropathy peripheral—Etoposide—germ cell cancer	0.000174	0.00184	CcSEcCtD
Erlotinib—Myocardial infarction—Etoposide—germ cell cancer	0.000174	0.00184	CcSEcCtD
Erlotinib—SLCO2B1—uterus—germ cell cancer	0.000174	0.00259	CbGeAlD
Erlotinib—ABL1—gonad—germ cell cancer	0.000174	0.00258	CbGeAlD
Erlotinib—Stomatitis—Etoposide—germ cell cancer	0.000173	0.00183	CcSEcCtD
Erlotinib—Decreased appetite—Vinblastine—germ cell cancer	0.000173	0.00182	CcSEcCtD
Erlotinib—ABL1—uterus—germ cell cancer	0.000172	0.00257	CbGeAlD
Erlotinib—Urinary tract disorder—Cisplatin—germ cell cancer	0.000172	0.00181	CcSEcCtD
Erlotinib—Connective tissue disorder—Cisplatin—germ cell cancer	0.000171	0.00181	CcSEcCtD
Erlotinib—Urethral disorder—Cisplatin—germ cell cancer	0.000171	0.0018	CcSEcCtD
Erlotinib—MAP2K5—endocrine gland—germ cell cancer	0.00017	0.00253	CbGeAlD
Erlotinib—Pain—Vinblastine—germ cell cancer	0.00017	0.00179	CcSEcCtD
Erlotinib—Constipation—Vinblastine—germ cell cancer	0.00017	0.00179	CcSEcCtD
Erlotinib—ULK3—lymph node—germ cell cancer	0.00017	0.00253	CbGeAlD
Erlotinib—ABL1—pituitary gland—germ cell cancer	0.000169	0.00252	CbGeAlD
Erlotinib—CYP1B1—skin of body—germ cell cancer	0.000168	0.0025	CbGeAlD
Erlotinib—Hepatobiliary disease—Etoposide—germ cell cancer	0.000168	0.00177	CcSEcCtD
Erlotinib—MAP2K5—head—germ cell cancer	0.000168	0.0025	CbGeAlD
Erlotinib—Oedema—Bleomycin—germ cell cancer	0.000168	0.00177	CcSEcCtD
Erlotinib—STK10—cerebellum—germ cell cancer	0.000168	0.0025	CbGeAlD
Erlotinib—ABCG2—trigeminal ganglion—germ cell cancer	0.000167	0.00249	CbGeAlD
Erlotinib—CYP1B1—decidua—germ cell cancer	0.000167	0.00249	CbGeAlD
Erlotinib—Infection—Bleomycin—germ cell cancer	0.000167	0.00176	CcSEcCtD
Erlotinib—MKNK1—brain—germ cell cancer	0.000165	0.00246	CbGeAlD
Erlotinib—Sepsis—Methotrexate—germ cell cancer	0.000165	0.00174	CcSEcCtD
Erlotinib—SLCO2B1—medulla oblongata—germ cell cancer	0.000165	0.00245	CbGeAlD
Erlotinib—Thrombocytopenia—Bleomycin—germ cell cancer	0.000164	0.00173	CcSEcCtD
Erlotinib—ABL1—medulla oblongata—germ cell cancer	0.000163	0.00243	CbGeAlD
Erlotinib—Myalgia—Dactinomycin—germ cell cancer	0.000163	0.00172	CcSEcCtD
Erlotinib—Eye disorder—Cisplatin—germ cell cancer	0.000163	0.00172	CcSEcCtD
Erlotinib—Gastrointestinal pain—Vinblastine—germ cell cancer	0.000162	0.00172	CcSEcCtD
Erlotinib—MAP2K5—testis—germ cell cancer	0.000162	0.00241	CbGeAlD
Erlotinib—Anorexia—Bleomycin—germ cell cancer	0.00016	0.00169	CcSEcCtD
Erlotinib—MKNK1—lymph node—germ cell cancer	0.00016	0.00238	CbGeAlD
Erlotinib—Urinary tract disorder—Etoposide—germ cell cancer	0.000157	0.00166	CcSEcCtD
Erlotinib—Abdominal pain—Vinblastine—germ cell cancer	0.000157	0.00166	CcSEcCtD
Erlotinib—Mediastinal disorder—Cisplatin—germ cell cancer	0.000157	0.00166	CcSEcCtD
Erlotinib—SLK—brain—germ cell cancer	0.000157	0.00233	CbGeAlD
Erlotinib—Oedema—Dactinomycin—germ cell cancer	0.000156	0.00165	CcSEcCtD
Erlotinib—Urethral disorder—Etoposide—germ cell cancer	0.000156	0.00165	CcSEcCtD
Erlotinib—Infection—Dactinomycin—germ cell cancer	0.000155	0.00164	CcSEcCtD
Erlotinib—Arrhythmia—Cisplatin—germ cell cancer	0.000155	0.00164	CcSEcCtD
Erlotinib—ORM1—bone marrow—germ cell cancer	0.000154	0.00229	CbGeAlD
Erlotinib—Alopecia—Cisplatin—germ cell cancer	0.000154	0.00162	CcSEcCtD
Erlotinib—Hepatic failure—Methotrexate—germ cell cancer	0.000154	0.00162	CcSEcCtD
Erlotinib—ORM1—spinal cord—germ cell cancer	0.000153	0.00228	CbGeAlD
Erlotinib—Cough—Ifosfamide—germ cell cancer	0.000153	0.00162	CcSEcCtD
Erlotinib—Thrombocytopenia—Dactinomycin—germ cell cancer	0.000153	0.00162	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.000153	0.00161	CcSEcCtD
Erlotinib—SLCO2B1—adrenal gland—germ cell cancer	0.000153	0.00227	CbGeAlD
Erlotinib—Erythema—Cisplatin—germ cell cancer	0.000151	0.0016	CcSEcCtD
Erlotinib—Malnutrition—Cisplatin—germ cell cancer	0.000151	0.0016	CcSEcCtD
Erlotinib—SLK—lymph node—germ cell cancer	0.000151	0.00225	CbGeAlD
Erlotinib—ABL1—adrenal gland—germ cell cancer	0.000151	0.00225	CbGeAlD
Erlotinib—Erythema multiforme—Etoposide—germ cell cancer	0.000151	0.00159	CcSEcCtD
Erlotinib—MAP2K5—cerebellum—germ cell cancer	0.00015	0.00223	CbGeAlD
Erlotinib—Dyspnoea—Bleomycin—germ cell cancer	0.00015	0.00158	CcSEcCtD
Erlotinib—Arthralgia—Ifosfamide—germ cell cancer	0.00015	0.00158	CcSEcCtD
Erlotinib—Myalgia—Ifosfamide—germ cell cancer	0.00015	0.00158	CcSEcCtD
Erlotinib—Chest pain—Ifosfamide—germ cell cancer	0.00015	0.00158	CcSEcCtD
Erlotinib—Renal failure acute—Methotrexate—germ cell cancer	0.000149	0.00158	CcSEcCtD
Erlotinib—ABL1—midbrain—germ cell cancer	0.000149	0.00222	CbGeAlD
Erlotinib—Flatulence—Cisplatin—germ cell cancer	0.000149	0.00158	CcSEcCtD
Erlotinib—Anorexia—Dactinomycin—germ cell cancer	0.000149	0.00157	CcSEcCtD
Erlotinib—Eye disorder—Etoposide—germ cell cancer	0.000149	0.00157	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.000149	0.00157	CcSEcCtD
Erlotinib—CYP1B1—gonad—germ cell cancer	0.000147	0.00219	CbGeAlD
Erlotinib—SLCO2B1—spinal cord—germ cell cancer	0.000147	0.00219	CbGeAlD
Erlotinib—ABL1—bone marrow—germ cell cancer	0.000146	0.00218	CbGeAlD
Erlotinib—CYP1B1—uterus—germ cell cancer	0.000146	0.00217	CbGeAlD
Erlotinib—Decreased appetite—Bleomycin—germ cell cancer	0.000146	0.00154	CcSEcCtD
Erlotinib—ABL1—spinal cord—germ cell cancer	0.000146	0.00217	CbGeAlD
Erlotinib—Mediastinal disorder—Etoposide—germ cell cancer	0.000144	0.00152	CcSEcCtD
Erlotinib—Pain—Bleomycin—germ cell cancer	0.000143	0.00151	CcSEcCtD
Erlotinib—CYP1B1—pituitary gland—germ cell cancer	0.000143	0.00214	CbGeAlD
Erlotinib—Oedema—Ifosfamide—germ cell cancer	0.000143	0.00151	CcSEcCtD
Erlotinib—Chills—Etoposide—germ cell cancer	0.000143	0.00151	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000143	0.00151	CcSEcCtD
Erlotinib—Asthenia—Vinblastine—germ cell cancer	0.000143	0.0015	CcSEcCtD
Erlotinib—Infection—Ifosfamide—germ cell cancer	0.000142	0.0015	CcSEcCtD
Erlotinib—SLCO2B1—female gonad—germ cell cancer	0.000142	0.00212	CbGeAlD
Erlotinib—ABL1—female gonad—germ cell cancer	0.000141	0.0021	CbGeAlD
Erlotinib—Alopecia—Etoposide—germ cell cancer	0.000141	0.00149	CcSEcCtD
Erlotinib—Cerebrovascular accident—Methotrexate—germ cell cancer	0.000141	0.00149	CcSEcCtD
Erlotinib—Nervous system disorder—Ifosfamide—germ cell cancer	0.000141	0.00148	CcSEcCtD
Erlotinib—Thrombocytopenia—Ifosfamide—germ cell cancer	0.00014	0.00148	CcSEcCtD
Erlotinib—ALB—adrenal gland—germ cell cancer	0.00014	0.00208	CbGeAlD
Erlotinib—Skin disorder—Ifosfamide—germ cell cancer	0.000139	0.00147	CcSEcCtD
Erlotinib—ORM1—endocrine gland—germ cell cancer	0.000138	0.00206	CbGeAlD
Erlotinib—Anorexia—Ifosfamide—germ cell cancer	0.000137	0.00144	CcSEcCtD
Erlotinib—STK10—brain—germ cell cancer	0.000136	0.00203	CbGeAlD
Erlotinib—Decreased appetite—Dactinomycin—germ cell cancer	0.000136	0.00144	CcSEcCtD
Erlotinib—Diarrhoea—Vinblastine—germ cell cancer	0.000136	0.00144	CcSEcCtD
Erlotinib—Fatigue—Dactinomycin—germ cell cancer	0.000135	0.00142	CcSEcCtD
Erlotinib—Back pain—Etoposide—germ cell cancer	0.000134	0.00142	CcSEcCtD
Erlotinib—Pain—Dactinomycin—germ cell cancer	0.000134	0.00141	CcSEcCtD
Erlotinib—ABCB1—blood vessel—germ cell cancer	0.000133	0.00198	CbGeAlD
Erlotinib—Body temperature increased—Bleomycin—germ cell cancer	0.000133	0.0014	CcSEcCtD
Erlotinib—SLCO2B1—endocrine gland—germ cell cancer	0.000132	0.00197	CbGeAlD
Erlotinib—STK10—lymph node—germ cell cancer	0.000132	0.00196	CbGeAlD
Erlotinib—Dizziness—Vinblastine—germ cell cancer	0.000131	0.00139	CcSEcCtD
Erlotinib—ABL1—endocrine gland—germ cell cancer	0.000131	0.00195	CbGeAlD
Erlotinib—ABCG2—telencephalon—germ cell cancer	0.000131	0.00195	CbGeAlD
Erlotinib—SLCO2B1—head—germ cell cancer	0.000131	0.00194	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000131	0.00138	CcSEcCtD
Erlotinib—ABL1—head—germ cell cancer	0.00013	0.00193	CbGeAlD
Erlotinib—Myalgia—Cisplatin—germ cell cancer	0.000129	0.00136	CcSEcCtD
Erlotinib—Anxiety—Cisplatin—germ cell cancer	0.000128	0.00136	CcSEcCtD
Erlotinib—CYP1B1—adrenal gland—germ cell cancer	0.000128	0.00191	CbGeAlD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.000128	0.00135	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dactinomycin—germ cell cancer	0.000128	0.00135	CcSEcCtD
Erlotinib—Dyspnoea—Ifosfamide—germ cell cancer	0.000128	0.00135	CcSEcCtD
Erlotinib—Vomiting—Vinblastine—germ cell cancer	0.000126	0.00133	CcSEcCtD
Erlotinib—SLCO2B1—testis—germ cell cancer	0.000126	0.00188	CbGeAlD
Erlotinib—ABL1—testis—germ cell cancer	0.000125	0.00186	CbGeAlD
Erlotinib—Decreased appetite—Ifosfamide—germ cell cancer	0.000125	0.00132	CcSEcCtD
Erlotinib—Headache—Vinblastine—germ cell cancer	0.000124	0.00131	CcSEcCtD
Erlotinib—ABCG2—decidua—germ cell cancer	0.000124	0.00185	CbGeAlD
Erlotinib—Toxic epidermal necrolysis—Methotrexate—germ cell cancer	0.000124	0.00131	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.000124	0.00131	CcSEcCtD
Erlotinib—Body temperature increased—Dactinomycin—germ cell cancer	0.000124	0.00131	CcSEcCtD
Erlotinib—Abdominal pain—Dactinomycin—germ cell cancer	0.000124	0.00131	CcSEcCtD
Erlotinib—Fatigue—Ifosfamide—germ cell cancer	0.000124	0.00131	CcSEcCtD
Erlotinib—Oedema—Cisplatin—germ cell cancer	0.000124	0.00131	CcSEcCtD
Erlotinib—Infection—Cisplatin—germ cell cancer	0.000123	0.0013	CcSEcCtD
Erlotinib—Constipation—Ifosfamide—germ cell cancer	0.000123	0.00129	CcSEcCtD
Erlotinib—Pain—Ifosfamide—germ cell cancer	0.000123	0.00129	CcSEcCtD
Erlotinib—Loss of consciousness—Etoposide—germ cell cancer	0.000122	0.00129	CcSEcCtD
Erlotinib—MAP2K5—brain—germ cell cancer	0.000122	0.00181	CbGeAlD
Erlotinib—Nervous system disorder—Cisplatin—germ cell cancer	0.000121	0.00128	CcSEcCtD
Erlotinib—Cough—Etoposide—germ cell cancer	0.000121	0.00128	CcSEcCtD
Erlotinib—Thrombocytopenia—Cisplatin—germ cell cancer	0.000121	0.00128	CcSEcCtD
Erlotinib—Asthenia—Bleomycin—germ cell cancer	0.00012	0.00127	CcSEcCtD
Erlotinib—Skin disorder—Cisplatin—germ cell cancer	0.00012	0.00127	CcSEcCtD
Erlotinib—CYP1B1—female gonad—germ cell cancer	0.000119	0.00178	CbGeAlD
Erlotinib—CYP1A1—skin of body—germ cell cancer	0.000119	0.00177	CbGeAlD
Erlotinib—Pruritus—Bleomycin—germ cell cancer	0.000119	0.00125	CcSEcCtD
Erlotinib—Chest pain—Etoposide—germ cell cancer	0.000118	0.00125	CcSEcCtD
Erlotinib—Nausea—Vinblastine—germ cell cancer	0.000118	0.00125	CcSEcCtD
Erlotinib—Anorexia—Cisplatin—germ cell cancer	0.000118	0.00124	CcSEcCtD
Erlotinib—MAP2K5—lymph node—germ cell cancer	0.000118	0.00175	CbGeAlD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	0.000117	0.00124	CcSEcCtD
Erlotinib—Gastrointestinal pain—Ifosfamide—germ cell cancer	0.000117	0.00124	CcSEcCtD
Erlotinib—Pancreatitis—Methotrexate—germ cell cancer	0.000117	0.00123	CcSEcCtD
Erlotinib—SLCO2B1—cerebellum—germ cell cancer	0.000117	0.00174	CbGeAlD
Erlotinib—ABL1—cerebellum—germ cell cancer	0.000116	0.00172	CbGeAlD
Erlotinib—ALB—testis—germ cell cancer	0.000115	0.00172	CbGeAlD
Erlotinib—Abdominal pain—Ifosfamide—germ cell cancer	0.000113	0.0012	CcSEcCtD
Erlotinib—Body temperature increased—Ifosfamide—germ cell cancer	0.000113	0.0012	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Cisplatin—germ cell cancer	0.000113	0.00119	CcSEcCtD
Erlotinib—Infection—Etoposide—germ cell cancer	0.000112	0.00119	CcSEcCtD
Erlotinib—Asthenia—Dactinomycin—germ cell cancer	0.000112	0.00119	CcSEcCtD
Erlotinib—Neutropenia—Methotrexate—germ cell cancer	0.000112	0.00118	CcSEcCtD
Erlotinib—CYP1B1—endocrine gland—germ cell cancer	0.000111	0.00165	CbGeAlD
Erlotinib—Thrombocytopenia—Etoposide—germ cell cancer	0.000111	0.00117	CcSEcCtD
Erlotinib—Dyspnoea—Cisplatin—germ cell cancer	0.00011	0.00116	CcSEcCtD
Erlotinib—Skin disorder—Etoposide—germ cell cancer	0.00011	0.00116	CcSEcCtD
Erlotinib—CYP2C8—pituitary gland—germ cell cancer	0.00011	0.00164	CbGeAlD
Erlotinib—CYP1B1—head—germ cell cancer	0.00011	0.00163	CbGeAlD
Erlotinib—ABCG2—uterus—germ cell cancer	0.000109	0.00162	CbGeAlD
Erlotinib—Anorexia—Etoposide—germ cell cancer	0.000108	0.00114	CcSEcCtD
Erlotinib—Decreased appetite—Cisplatin—germ cell cancer	0.000107	0.00113	CcSEcCtD
Erlotinib—Diarrhoea—Dactinomycin—germ cell cancer	0.000107	0.00113	CcSEcCtD
Erlotinib—Pneumonia—Methotrexate—germ cell cancer	0.000107	0.00113	CcSEcCtD
Erlotinib—ABCG2—pituitary gland—germ cell cancer	0.000107	0.00159	CbGeAlD
Erlotinib—Gastrointestinal disorder—Cisplatin—germ cell cancer	0.000107	0.00113	CcSEcCtD
Erlotinib—Vomiting—Bleomycin—germ cell cancer	0.000107	0.00113	CcSEcCtD
Erlotinib—Infestation NOS—Methotrexate—germ cell cancer	0.000106	0.00112	CcSEcCtD
Erlotinib—Infestation—Methotrexate—germ cell cancer	0.000106	0.00112	CcSEcCtD
Erlotinib—Depression—Methotrexate—germ cell cancer	0.000106	0.00112	CcSEcCtD
Erlotinib—CYP1B1—testis—germ cell cancer	0.000106	0.00158	CbGeAlD
Erlotinib—Rash—Bleomycin—germ cell cancer	0.000106	0.00112	CcSEcCtD
Erlotinib—Pain—Cisplatin—germ cell cancer	0.000106	0.00112	CcSEcCtD
Erlotinib—Dermatitis—Bleomycin—germ cell cancer	0.000106	0.00112	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Methotrexate—germ cell cancer	0.000105	0.00111	CcSEcCtD
Erlotinib—Renal failure—Methotrexate—germ cell cancer	0.000105	0.0011	CcSEcCtD
Erlotinib—Stomatitis—Methotrexate—germ cell cancer	0.000104	0.00109	CcSEcCtD
Erlotinib—Conjunctivitis—Methotrexate—germ cell cancer	0.000103	0.00109	CcSEcCtD
Erlotinib—CYP1A1—uterus—germ cell cancer	0.000103	0.00154	CbGeAlD
Erlotinib—ABCG2—medulla oblongata—germ cell cancer	0.000103	0.00153	CbGeAlD
Erlotinib—Asthenia—Ifosfamide—germ cell cancer	0.000103	0.00109	CcSEcCtD
Erlotinib—Pruritus—Ifosfamide—germ cell cancer	0.000101	0.00107	CcSEcCtD
Erlotinib—CYP2D6—brainstem—germ cell cancer	0.000101	0.00151	CbGeAlD
Erlotinib—Dyspnoea—Etoposide—germ cell cancer	0.000101	0.00107	CcSEcCtD
Erlotinib—Hepatobiliary disease—Methotrexate—germ cell cancer	0.000101	0.00106	CcSEcCtD
Erlotinib—Epistaxis—Methotrexate—germ cell cancer	0.0001	0.00106	CcSEcCtD
Erlotinib—Nausea—Bleomycin—germ cell cancer	9.96e-05	0.00105	CcSEcCtD
Erlotinib—Vomiting—Dactinomycin—germ cell cancer	9.95e-05	0.00105	CcSEcCtD
Erlotinib—Rash—Dactinomycin—germ cell cancer	9.86e-05	0.00104	CcSEcCtD
Erlotinib—Decreased appetite—Etoposide—germ cell cancer	9.84e-05	0.00104	CcSEcCtD
Erlotinib—Diarrhoea—Ifosfamide—germ cell cancer	9.81e-05	0.00104	CcSEcCtD
Erlotinib—CYP1B1—cerebellum—germ cell cancer	9.79e-05	0.00146	CbGeAlD
Erlotinib—Gastrointestinal disorder—Etoposide—germ cell cancer	9.78e-05	0.00103	CcSEcCtD
Erlotinib—Body temperature increased—Cisplatin—germ cell cancer	9.77e-05	0.00103	CcSEcCtD
Erlotinib—Fatigue—Etoposide—germ cell cancer	9.76e-05	0.00103	CcSEcCtD
Erlotinib—Pain—Etoposide—germ cell cancer	9.68e-05	0.00102	CcSEcCtD
Erlotinib—Constipation—Etoposide—germ cell cancer	9.68e-05	0.00102	CcSEcCtD
Erlotinib—Haemoglobin—Methotrexate—germ cell cancer	9.6e-05	0.00101	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—germ cell cancer	9.55e-05	0.00101	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—germ cell cancer	9.55e-05	0.00101	CcSEcCtD
Erlotinib—ORM1—lymph node—germ cell cancer	9.54e-05	0.00142	CbGeAlD
Erlotinib—ABCG2—adrenal gland—germ cell cancer	9.54e-05	0.00142	CbGeAlD
Erlotinib—Dizziness—Ifosfamide—germ cell cancer	9.48e-05	0.001	CcSEcCtD
Erlotinib—SLCO2B1—brain—germ cell cancer	9.47e-05	0.00141	CbGeAlD
Erlotinib—Urinary tract disorder—Methotrexate—germ cell cancer	9.43e-05	0.000996	CcSEcCtD
Erlotinib—ABCG2—midbrain—germ cell cancer	9.42e-05	0.0014	CbGeAlD
Erlotinib—ABL1—brain—germ cell cancer	9.39e-05	0.0014	CbGeAlD
Erlotinib—Urethral disorder—Methotrexate—germ cell cancer	9.36e-05	0.000988	CcSEcCtD
Erlotinib—Nausea—Dactinomycin—germ cell cancer	9.29e-05	0.000981	CcSEcCtD
Erlotinib—Gastrointestinal pain—Etoposide—germ cell cancer	9.26e-05	0.000978	CcSEcCtD
Erlotinib—ABCG2—bone marrow—germ cell cancer	9.23e-05	0.00137	CbGeAlD
Erlotinib—ABCG2—spinal cord—germ cell cancer	9.19e-05	0.00137	CbGeAlD
Erlotinib—SLCO2B1—lymph node—germ cell cancer	9.15e-05	0.00136	CbGeAlD
Erlotinib—Vomiting—Ifosfamide—germ cell cancer	9.12e-05	0.000963	CcSEcCtD
Erlotinib—ABL1—lymph node—germ cell cancer	9.07e-05	0.00135	CbGeAlD
Erlotinib—Rash—Ifosfamide—germ cell cancer	9.04e-05	0.000955	CcSEcCtD
Erlotinib—Dermatitis—Ifosfamide—germ cell cancer	9.03e-05	0.000954	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—germ cell cancer	9.03e-05	0.000953	CcSEcCtD
Erlotinib—CYP2D6—telencephalon—germ cell cancer	8.99e-05	0.00134	CbGeAlD
Erlotinib—Abdominal pain—Etoposide—germ cell cancer	8.95e-05	0.000945	CcSEcCtD
Erlotinib—Body temperature increased—Etoposide—germ cell cancer	8.95e-05	0.000945	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—germ cell cancer	8.92e-05	0.000942	CcSEcCtD
Erlotinib—ABCG2—female gonad—germ cell cancer	8.9e-05	0.00132	CbGeAlD
Erlotinib—Asthenia—Cisplatin—germ cell cancer	8.87e-05	0.000936	CcSEcCtD
Erlotinib—ALB—brain—germ cell cancer	8.66e-05	0.00129	CbGeAlD
Erlotinib—Mediastinal disorder—Methotrexate—germ cell cancer	8.6e-05	0.000909	CcSEcCtD
Erlotinib—Chills—Methotrexate—germ cell cancer	8.57e-05	0.000905	CcSEcCtD
Erlotinib—Nausea—Ifosfamide—germ cell cancer	8.52e-05	0.000899	CcSEcCtD
Erlotinib—CYP2C8—endocrine gland—germ cell cancer	8.51e-05	0.00127	CbGeAlD
Erlotinib—Diarrhoea—Cisplatin—germ cell cancer	8.46e-05	0.000893	CcSEcCtD
Erlotinib—CYP1A1—female gonad—germ cell cancer	8.44e-05	0.00126	CbGeAlD
Erlotinib—Alopecia—Methotrexate—germ cell cancer	8.44e-05	0.000891	CcSEcCtD
Erlotinib—ALB—lymph node—germ cell cancer	8.37e-05	0.00125	CbGeAlD
Erlotinib—Mental disorder—Methotrexate—germ cell cancer	8.36e-05	0.000883	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—germ cell cancer	8.31e-05	0.000878	CcSEcCtD
Erlotinib—Erythema—Methotrexate—germ cell cancer	8.31e-05	0.000878	CcSEcCtD
Erlotinib—CYP3A5—female gonad—germ cell cancer	8.26e-05	0.00123	CbGeAlD
Erlotinib—ABCB1—trigeminal ganglion—germ cell cancer	8.24e-05	0.00123	CbGeAlD
Erlotinib—Asthenia—Etoposide—germ cell cancer	8.12e-05	0.000858	CcSEcCtD
Erlotinib—CYP2C8—testis—germ cell cancer	8.11e-05	0.00121	CbGeAlD
Erlotinib—Back pain—Methotrexate—germ cell cancer	8.04e-05	0.000849	CcSEcCtD
Erlotinib—Pruritus—Etoposide—germ cell cancer	8.01e-05	0.000846	CcSEcCtD
Erlotinib—CYP1A2—endocrine gland—germ cell cancer	7.96e-05	0.00119	CbGeAlD
Erlotinib—ABCB1—embryo—germ cell cancer	7.95e-05	0.00118	CbGeAlD
Erlotinib—CYP1B1—brain—germ cell cancer	7.95e-05	0.00118	CbGeAlD
Erlotinib—ABCG2—testis—germ cell cancer	7.89e-05	0.00117	CbGeAlD
Erlotinib—Vomiting—Cisplatin—germ cell cancer	7.86e-05	0.00083	CcSEcCtD
Erlotinib—CYP1A1—endocrine gland—germ cell cancer	7.85e-05	0.00117	CbGeAlD
Erlotinib—Rash—Cisplatin—germ cell cancer	7.79e-05	0.000823	CcSEcCtD
Erlotinib—Dermatitis—Cisplatin—germ cell cancer	7.79e-05	0.000822	CcSEcCtD
Erlotinib—CYP1A1—head—germ cell cancer	7.75e-05	0.00115	CbGeAlD
Erlotinib—Diarrhoea—Etoposide—germ cell cancer	7.75e-05	0.000818	CcSEcCtD
Erlotinib—CYP1B1—lymph node—germ cell cancer	7.68e-05	0.00114	CbGeAlD
Erlotinib—CYP3A5—endocrine gland—germ cell cancer	7.68e-05	0.00114	CbGeAlD
Erlotinib—Dizziness—Etoposide—germ cell cancer	7.49e-05	0.000791	CcSEcCtD
Erlotinib—Nausea—Cisplatin—germ cell cancer	7.34e-05	0.000775	CcSEcCtD
Erlotinib—ABCG2—cerebellum—germ cell cancer	7.29e-05	0.00108	CbGeAlD
Erlotinib—Cough—Methotrexate—germ cell cancer	7.25e-05	0.000766	CcSEcCtD
Erlotinib—Vomiting—Etoposide—germ cell cancer	7.2e-05	0.00076	CcSEcCtD
Erlotinib—Rash—Etoposide—germ cell cancer	7.14e-05	0.000754	CcSEcCtD
Erlotinib—Dermatitis—Etoposide—germ cell cancer	7.13e-05	0.000753	CcSEcCtD
Erlotinib—Headache—Etoposide—germ cell cancer	7.09e-05	0.000749	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—germ cell cancer	7.08e-05	0.000747	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—germ cell cancer	7.08e-05	0.000747	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—germ cell cancer	7.08e-05	0.000747	CcSEcCtD
Erlotinib—ABCB1—retina—germ cell cancer	7.03e-05	0.00105	CbGeAlD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	7.03e-05	0.000742	CcSEcCtD
Erlotinib—Infection—Methotrexate—germ cell cancer	6.74e-05	0.000712	CcSEcCtD
Erlotinib—Nausea—Etoposide—germ cell cancer	6.73e-05	0.00071	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—germ cell cancer	6.65e-05	0.000702	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—germ cell cancer	6.64e-05	0.000701	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—germ cell cancer	6.59e-05	0.000696	CcSEcCtD
Erlotinib—ABCB1—telencephalon—germ cell cancer	6.47e-05	0.000963	CbGeAlD
Erlotinib—Anorexia—Methotrexate—germ cell cancer	6.47e-05	0.000683	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—germ cell cancer	6.18e-05	0.000653	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—germ cell cancer	6.13e-05	0.000648	CcSEcCtD
Erlotinib—ABCB1—decidua—germ cell cancer	6.13e-05	0.000913	CbGeAlD
Erlotinib—CYP2D6—female gonad—germ cell cancer	6.1e-05	0.000908	CbGeAlD
Erlotinib—CYP2C8—brain—germ cell cancer	6.09e-05	0.000906	CbGeAlD
Erlotinib—Dyspnoea—Methotrexate—germ cell cancer	6.05e-05	0.000639	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—germ cell cancer	5.97e-05	0.00063	CcSEcCtD
Erlotinib—ABCG2—brain—germ cell cancer	5.92e-05	0.000881	CbGeAlD
Erlotinib—Decreased appetite—Methotrexate—germ cell cancer	5.9e-05	0.000623	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—germ cell cancer	5.86e-05	0.000618	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—germ cell cancer	5.85e-05	0.000618	CcSEcCtD
Erlotinib—Pain—Methotrexate—germ cell cancer	5.8e-05	0.000612	CcSEcCtD
Erlotinib—CYP3A4—endocrine gland—germ cell cancer	5.76e-05	0.000858	CbGeAlD
Erlotinib—ABCG2—lymph node—germ cell cancer	5.72e-05	0.000851	CbGeAlD
Erlotinib—CYP2D6—endocrine gland—germ cell cancer	5.67e-05	0.000844	CbGeAlD
Erlotinib—CYP1A1—brain—germ cell cancer	5.62e-05	0.000837	CbGeAlD
Erlotinib—CYP2D6—head—germ cell cancer	5.6e-05	0.000834	CbGeAlD
Erlotinib—Gastrointestinal pain—Methotrexate—germ cell cancer	5.55e-05	0.000586	CcSEcCtD
Erlotinib—CYP1A1—lymph node—germ cell cancer	5.43e-05	0.000808	CbGeAlD
Erlotinib—CYP2D6—testis—germ cell cancer	5.41e-05	0.000805	CbGeAlD
Erlotinib—ABCB1—gonad—germ cell cancer	5.4e-05	0.000804	CbGeAlD
Erlotinib—ABCB1—uterus—germ cell cancer	5.36e-05	0.000798	CbGeAlD
Erlotinib—Body temperature increased—Methotrexate—germ cell cancer	5.36e-05	0.000566	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—germ cell cancer	5.36e-05	0.000566	CcSEcCtD
Erlotinib—ABCB1—pituitary gland—germ cell cancer	5.27e-05	0.000784	CbGeAlD
Erlotinib—ABCB1—medulla oblongata—germ cell cancer	5.08e-05	0.000757	CbGeAlD
Erlotinib—CYP2D6—cerebellum—germ cell cancer	4.99e-05	0.000744	CbGeAlD
Erlotinib—Asthenia—Methotrexate—germ cell cancer	4.87e-05	0.000514	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—germ cell cancer	4.8e-05	0.000507	CcSEcCtD
Erlotinib—ABCB1—adrenal gland—germ cell cancer	4.7e-05	0.0007	CbGeAlD
Erlotinib—ABCB1—midbrain—germ cell cancer	4.64e-05	0.000691	CbGeAlD
Erlotinib—Diarrhoea—Methotrexate—germ cell cancer	4.64e-05	0.00049	CcSEcCtD
Erlotinib—ABCB1—bone marrow—germ cell cancer	4.55e-05	0.000678	CbGeAlD
Erlotinib—ABCB1—spinal cord—germ cell cancer	4.53e-05	0.000675	CbGeAlD
Erlotinib—Dizziness—Methotrexate—germ cell cancer	4.49e-05	0.000474	CcSEcCtD
Erlotinib—ABCB1—female gonad—germ cell cancer	4.39e-05	0.000653	CbGeAlD
Erlotinib—Vomiting—Methotrexate—germ cell cancer	4.31e-05	0.000455	CcSEcCtD
Erlotinib—Rash—Methotrexate—germ cell cancer	4.28e-05	0.000452	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—germ cell cancer	4.27e-05	0.000451	CcSEcCtD
Erlotinib—Headache—Methotrexate—germ cell cancer	4.25e-05	0.000449	CcSEcCtD
Erlotinib—ABCB1—endocrine gland—germ cell cancer	4.08e-05	0.000607	CbGeAlD
Erlotinib—CYP2D6—brain—germ cell cancer	4.06e-05	0.000604	CbGeAlD
Erlotinib—Nausea—Methotrexate—germ cell cancer	4.03e-05	0.000425	CcSEcCtD
Erlotinib—ABCB1—head—germ cell cancer	4.03e-05	0.0006	CbGeAlD
Erlotinib—ABCB1—testis—germ cell cancer	3.89e-05	0.000579	CbGeAlD
Erlotinib—ABCG2—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	3.64e-05	0.000997	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—FGFR3—germ cell cancer	3.63e-05	0.000993	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—KIT—germ cell cancer	3.63e-05	0.000992	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—KIT—germ cell cancer	3.61e-05	0.000988	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—FGFR3—germ cell cancer	3.6e-05	0.000984	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—SOX2—germ cell cancer	3.59e-05	0.000984	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—MYC—germ cell cancer	3.59e-05	0.000984	CbGpPWpGaD
Erlotinib—ABCB1—cerebellum—germ cell cancer	3.59e-05	0.000535	CbGeAlD
Erlotinib—EGFR—Signaling by ERBB2—KIT—germ cell cancer	3.59e-05	0.000983	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	3.59e-05	0.000982	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—FGFR3—germ cell cancer	3.58e-05	0.00098	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—KIT—germ cell cancer	3.57e-05	0.000978	CbGpPWpGaD
Erlotinib—EGFR—SHP2 signaling—HRAS—germ cell cancer	3.55e-05	0.000971	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PVRL2—germ cell cancer	3.54e-05	0.000969	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—germ cell cancer	3.52e-05	0.000964	CbGpPWpGaD
Erlotinib—SLCO2B1—Transmembrane transport of small molecules—AVP—germ cell cancer	3.46e-05	0.000946	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor—MYC—germ cell cancer	3.44e-05	0.00094	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SCNN1A—germ cell cancer	3.43e-05	0.00094	CbGpPWpGaD
Erlotinib—MKNK1—Disease—H2AFZ—germ cell cancer	3.39e-05	0.000928	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—FGFR3—germ cell cancer	3.39e-05	0.000927	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	3.38e-05	0.000925	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—KIT—germ cell cancer	3.36e-05	0.00092	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—germ cell cancer	3.36e-05	0.00092	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—KIT—germ cell cancer	3.36e-05	0.00092	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KITLG—germ cell cancer	3.36e-05	0.000918	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—KIT—germ cell cancer	3.33e-05	0.000912	CbGpPWpGaD
Erlotinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—germ cell cancer	3.3e-05	0.000904	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—KIT—germ cell cancer	3.3e-05	0.000904	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—KIT—germ cell cancer	3.29e-05	0.0009	CbGpPWpGaD
Erlotinib—EGFR—LPA receptor mediated events—HRAS—germ cell cancer	3.28e-05	0.000897	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—FGFR3—germ cell cancer	3.24e-05	0.000888	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—H2AFZ—germ cell cancer	3.24e-05	0.000887	CbGpPWpGaD
Erlotinib—MAP2K5—BDNF signaling pathway—HRAS—germ cell cancer	3.19e-05	0.000874	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—MYC—germ cell cancer	3.19e-05	0.000873	CbGpPWpGaD
Erlotinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—HRAS—germ cell cancer	3.16e-05	0.000865	CbGpPWpGaD
Erlotinib—ABL1—Retinoblastoma (RB) in Cancer—TP53—germ cell cancer	3.14e-05	0.000859	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KITLG—germ cell cancer	3.12e-05	0.000854	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—OXT—germ cell cancer	3.12e-05	0.000853	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—KIT—germ cell cancer	3.11e-05	0.000851	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGF4—germ cell cancer	3.1e-05	0.000849	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SCNN1A—germ cell cancer	3.01e-05	0.000824	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—AVP—germ cell cancer	3e-05	0.000822	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—germ cell cancer	2.98e-05	0.000815	CbGpPWpGaD
Erlotinib—ABL2—Axon guidance—HRAS—germ cell cancer	2.97e-05	0.000812	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—TP53—germ cell cancer	2.95e-05	0.000808	CbGpPWpGaD
Erlotinib—MAP2K5—Insulin Signaling—HRAS—germ cell cancer	2.94e-05	0.000803	CbGpPWpGaD
Erlotinib—ABCB1—brain—germ cell cancer	2.92e-05	0.000435	CbGeAlD
Erlotinib—MAP2K5—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	2.91e-05	0.000795	CbGpPWpGaD
Erlotinib—ABL1—PDGFR-beta signaling pathway—MYC—germ cell cancer	2.86e-05	0.000783	CbGpPWpGaD
Erlotinib—ABCB1—lymph node—germ cell cancer	2.82e-05	0.00042	CbGeAlD
Erlotinib—EGFR—Signaling Pathways in Glioblastoma—TP53—germ cell cancer	2.81e-05	0.000769	CbGpPWpGaD
Erlotinib—ABL1—Cell Cycle—TP53—germ cell cancer	2.76e-05	0.000756	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGF4—germ cell cancer	2.73e-05	0.000746	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—AVP—germ cell cancer	2.73e-05	0.000746	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—germ cell cancer	2.7e-05	0.000738	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways in Glioblastoma—HRAS—germ cell cancer	2.69e-05	0.000736	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGF4—germ cell cancer	2.66e-05	0.000728	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—germ cell cancer	2.62e-05	0.000717	CbGpPWpGaD
Erlotinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—germ cell cancer	2.61e-05	0.000714	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—MYC—germ cell cancer	2.56e-05	0.0007	CbGpPWpGaD
Erlotinib—MAP2K5—Focal Adhesion—HRAS—germ cell cancer	2.56e-05	0.0007	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KITLG—germ cell cancer	2.55e-05	0.000698	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—CD9—germ cell cancer	2.52e-05	0.00069	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PVRL2—germ cell cancer	2.51e-05	0.000688	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—HRAS—germ cell cancer	2.51e-05	0.000686	CbGpPWpGaD
Erlotinib—EPHA6—Axon guidance—HRAS—germ cell cancer	2.5e-05	0.000685	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FGFR3—germ cell cancer	2.49e-05	0.000683	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—MYC—germ cell cancer	2.46e-05	0.000673	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	2.4e-05	0.000656	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—H2AFZ—germ cell cancer	2.38e-05	0.00065	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—OXT—germ cell cancer	2.35e-05	0.000643	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGF4—germ cell cancer	2.33e-05	0.000638	CbGpPWpGaD
Erlotinib—NR1I2—Generic Transcription Pathway—MYC—germ cell cancer	2.32e-05	0.000636	CbGpPWpGaD
Erlotinib—MKNK1—Disease—FGFR3—germ cell cancer	2.32e-05	0.000635	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—HRAS—germ cell cancer	2.3e-05	0.00063	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KIT—germ cell cancer	2.29e-05	0.000627	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	2.25e-05	0.000615	CbGpPWpGaD
Erlotinib—ABL1—PDGFR-beta signaling pathway—HRAS—germ cell cancer	2.25e-05	0.000615	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KITLG—germ cell cancer	2.24e-05	0.000613	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGF4—germ cell cancer	2.24e-05	0.000612	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	2.21e-05	0.000606	CbGpPWpGaD
Erlotinib—EGFR—ErbB1 downstream signaling—HRAS—germ cell cancer	2.21e-05	0.000604	CbGpPWpGaD
Erlotinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—germ cell cancer	2.19e-05	0.000601	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—MYC—germ cell cancer	2.19e-05	0.000599	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KITLG—germ cell cancer	2.19e-05	0.000598	CbGpPWpGaD
Erlotinib—EGFR—Disease—SLC2A3—germ cell cancer	2.18e-05	0.000597	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PVRL2—germ cell cancer	2.15e-05	0.000588	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AVP—germ cell cancer	2.14e-05	0.000585	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KIT—germ cell cancer	2.13e-05	0.000583	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—HRAS—germ cell cancer	2.12e-05	0.00058	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TP53—germ cell cancer	2.1e-05	0.000575	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—MYC—germ cell cancer	2.1e-05	0.000575	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	2.08e-05	0.00057	CbGpPWpGaD
Erlotinib—ALB—SLC-mediated transmembrane transport—AVP—germ cell cancer	2.04e-05	0.000558	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	2.04e-05	0.000557	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—TP53—germ cell cancer	2.02e-05	0.000552	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—SLC2A3—germ cell cancer	2.01e-05	0.00055	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGF4—germ cell cancer	2.01e-05	0.000549	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—SLC22A3—germ cell cancer	1.98e-05	0.000542	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	1.97e-05	0.000539	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	1.94e-05	0.000531	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—MYC—germ cell cancer	1.93e-05	0.000528	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TP53—germ cell cancer	1.93e-05	0.000527	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—OXT—germ cell cancer	1.92e-05	0.000524	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KITLG—germ cell cancer	1.91e-05	0.000524	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	1.91e-05	0.000522	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	1.9e-05	0.000519	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGFR3—germ cell cancer	1.89e-05	0.000518	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—SLC2A3—germ cell cancer	1.87e-05	0.000513	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—SLC22A3—germ cell cancer	1.85e-05	0.000505	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—HRAS—germ cell cancer	1.84e-05	0.000505	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KITLG—germ cell cancer	1.84e-05	0.000503	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—germ cell cancer	1.83e-05	0.000502	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	1.82e-05	0.000499	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—H2AFZ—germ cell cancer	1.79e-05	0.00049	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—HRAS—germ cell cancer	1.79e-05	0.000489	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—HRAS—germ cell cancer	1.74e-05	0.000477	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	1.74e-05	0.000476	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—OXT—germ cell cancer	1.74e-05	0.000476	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KIT—germ cell cancer	1.74e-05	0.000476	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—germ cell cancer	1.72e-05	0.000472	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—germ cell cancer	1.72e-05	0.000471	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—SLC2A3—germ cell cancer	1.71e-05	0.000467	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—SLC22A3—germ cell cancer	1.68e-05	0.00046	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—AVP—germ cell cancer	1.68e-05	0.00046	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	1.67e-05	0.000458	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—HRAS—germ cell cancer	1.67e-05	0.000456	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGFR3—germ cell cancer	1.66e-05	0.000456	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KITLG—germ cell cancer	1.65e-05	0.000451	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—HRAS—germ cell cancer	1.64e-05	0.000449	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGF4—germ cell cancer	1.64e-05	0.000447	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGFR3—germ cell cancer	1.62e-05	0.000444	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CRABP1—germ cell cancer	1.61e-05	0.000442	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AVP—germ cell cancer	1.61e-05	0.000441	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGF4—germ cell cancer	1.59e-05	0.000435	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—germ cell cancer	1.58e-05	0.000433	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—HRAS—germ cell cancer	1.57e-05	0.000429	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	1.56e-05	0.000427	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—HRAS—germ cell cancer	1.56e-05	0.000427	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—HRAS—germ cell cancer	1.55e-05	0.000425	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—HRAS—germ cell cancer	1.54e-05	0.000423	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KIT—germ cell cancer	1.53e-05	0.000418	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	1.52e-05	0.000417	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CRABP1—germ cell cancer	1.51e-05	0.000412	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—germ cell cancer	1.5e-05	0.00041	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KIT—germ cell cancer	1.49e-05	0.000408	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—H2AFZ—germ cell cancer	1.46e-05	0.0004	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—HRAS—germ cell cancer	1.45e-05	0.000398	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	1.45e-05	0.000398	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—HRAS—germ cell cancer	1.45e-05	0.000398	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—HRAS—germ cell cancer	1.44e-05	0.000394	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—HRAS—germ cell cancer	1.43e-05	0.000392	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	1.43e-05	0.000391	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—HRAS—germ cell cancer	1.43e-05	0.000391	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGFR3—germ cell cancer	1.42e-05	0.000389	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—HRAS—germ cell cancer	1.42e-05	0.000389	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—HRAS—germ cell cancer	1.37e-05	0.000376	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CRABP1—germ cell cancer	1.37e-05	0.000375	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGFR3—germ cell cancer	1.37e-05	0.000374	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGF4—germ cell cancer	1.36e-05	0.000371	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—HRAS—germ cell cancer	1.34e-05	0.000368	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KITLG—germ cell cancer	1.34e-05	0.000368	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	1.33e-05	0.000363	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AVP—germ cell cancer	1.31e-05	0.000359	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KIT—germ cell cancer	1.31e-05	0.000357	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KITLG—germ cell cancer	1.3e-05	0.000357	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	1.29e-05	0.000352	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KIT—germ cell cancer	1.25e-05	0.000343	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGF4—germ cell cancer	1.25e-05	0.000343	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—germ cell cancer	1.24e-05	0.00034	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGFR3—germ cell cancer	1.22e-05	0.000335	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SLC2A3—germ cell cancer	1.22e-05	0.000334	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SLC22A3—germ cell cancer	1.2e-05	0.000329	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AVP—germ cell cancer	1.19e-05	0.000326	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MYC—germ cell cancer	1.17e-05	0.000321	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC2A3—germ cell cancer	1.15e-05	0.000316	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC22A3—germ cell cancer	1.14e-05	0.000311	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KIT—germ cell cancer	1.12e-05	0.000308	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—MYC—germ cell cancer	1.12e-05	0.000306	CbGpPWpGaD
Erlotinib—EGFR—Disease—H2AFZ—germ cell cancer	1.12e-05	0.000306	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KITLG—germ cell cancer	1.11e-05	0.000305	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC2A3—germ cell cancer	1.06e-05	0.00029	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC2A3—germ cell cancer	1.05e-05	0.000288	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—HRAS—germ cell cancer	1.05e-05	0.000287	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC22A3—germ cell cancer	1.04e-05	0.000285	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC22A3—germ cell cancer	1.04e-05	0.000284	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—AVP—germ cell cancer	1.04e-05	0.000284	CbGpPWpGaD
Erlotinib—EGFR—Disease—KITLG—germ cell cancer	1.03e-05	0.000282	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—OXT—germ cell cancer	1.03e-05	0.000281	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGFR3—germ cell cancer	9.98e-06	0.000273	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—HRAS—germ cell cancer	9.9e-06	0.000271	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CRABP1—germ cell cancer	9.81e-06	0.000269	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGFR3—germ cell cancer	9.7e-06	0.000265	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CRABP1—germ cell cancer	9.27e-06	0.000254	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC2A3—germ cell cancer	9.22e-06	0.000252	CbGpPWpGaD
Erlotinib—MKNK1—Disease—HRAS—germ cell cancer	9.2e-06	0.000252	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KIT—germ cell cancer	9.17e-06	0.000251	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC22A3—germ cell cancer	9.08e-06	0.000249	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—AVP—germ cell cancer	9.08e-06	0.000249	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—HRAS—germ cell cancer	8.96e-06	0.000245	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KIT—germ cell cancer	8.9e-06	0.000244	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	8.78e-06	0.00024	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF4—germ cell cancer	8.77e-06	0.00024	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC2A3—germ cell cancer	8.69e-06	0.000238	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC22A3—germ cell cancer	8.56e-06	0.000234	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CRABP1—germ cell cancer	8.5e-06	0.000233	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CRABP1—germ cell cancer	8.45e-06	0.000231	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGFR3—germ cell cancer	8.29e-06	0.000227	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HRAS—germ cell cancer	8.23e-06	0.000225	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MYC—germ cell cancer	8.2e-06	0.000225	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—H2AFZ—germ cell cancer	7.84e-06	0.000214	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—germ cell cancer	7.67e-06	0.00021	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGFR3—germ cell cancer	7.65e-06	0.000209	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KIT—germ cell cancer	7.61e-06	0.000208	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—germ cell cancer	7.52e-06	0.000206	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—germ cell cancer	7.48e-06	0.000205	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CRABP1—germ cell cancer	7.4e-06	0.000203	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC2A3—germ cell cancer	7.36e-06	0.000201	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—germ cell cancer	7.34e-06	0.000201	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC22A3—germ cell cancer	7.25e-06	0.000198	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	7.21e-06	0.000197	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KITLG—germ cell cancer	7.21e-06	0.000197	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AVP—germ cell cancer	7.05e-06	0.000193	CbGpPWpGaD
Erlotinib—EGFR—Disease—KIT—germ cell cancer	7.02e-06	0.000192	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CRABP1—germ cell cancer	6.98e-06	0.000191	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—germ cell cancer	6.74e-06	0.000184	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—germ cell cancer	6.61e-06	0.000181	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—germ cell cancer	6.44e-06	0.000176	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—germ cell cancer	6.39e-06	0.000175	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MYC—germ cell cancer	6.19e-06	0.000169	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CRABP1—germ cell cancer	5.91e-06	0.000162	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A3—germ cell cancer	5.68e-06	0.000155	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—germ cell cancer	5.64e-06	0.000154	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC22A3—germ cell cancer	5.6e-06	0.000153	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—germ cell cancer	5.42e-06	0.000148	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR3—germ cell cancer	5.36e-06	0.000147	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—germ cell cancer	5.08e-06	0.000139	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—germ cell cancer	5.04e-06	0.000138	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KIT—germ cell cancer	4.92e-06	0.000135	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—germ cell cancer	4.86e-06	0.000133	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CRABP1—germ cell cancer	4.56e-06	0.000125	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—germ cell cancer	4.14e-06	0.000113	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—germ cell cancer	3.96e-06	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—germ cell cancer	3.86e-06	0.000106	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—germ cell cancer	3.85e-06	0.000105	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—germ cell cancer	3.78e-06	0.000103	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—germ cell cancer	3.61e-06	9.88e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—germ cell cancer	3.6e-06	9.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—germ cell cancer	3.29e-06	9e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—germ cell cancer	3.04e-06	8.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—germ cell cancer	2.71e-06	7.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—germ cell cancer	2.22e-06	6.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—germ cell cancer	2.13e-06	5.82e-05	CbGpPWpGaD
